The FDA approved pegcetacoplan (EMPAVELI; Apellis Pharmaceuticals) as the first treatment for patients aged 12 and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

Dozens of lawmakers are urging U.S. health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

An unusual FDA panel on antidepressant use during pregnancy elevated clinicians and researchers who are deeply skeptical of ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...